Under the continuous investment in research and development, the income of many pharmaceutical companies in innovative drugs has reached a new high!

【Pharmaceutical Network Industry News】At present, the 2022 interim report of listed pharmaceutical companies has been disclosed one after another, and it can be seen from the reports of many pharmaceutical companies that through continuous investment in research and development, a number of pharmaceutical companies have achieved great results in innovative drugs, driving high revenue growth
in the first half of the year.

Under the continuous investment in research and development, the income of many pharmaceutical companies in innovative drugs has reached a new high! For example, the 2022 semi-annual report released by Simcere Pharmaceutical on August 31 showed that the revenue of innovative drugs in the first half of the year was 1.
767 billion yuan, an increase of 44.
8% year-on-year, accounting for 65.
4% of the total revenue of 2.
700 billion yuan, a record high
.

According to the interim report disclosed by China Biopharmaceutical on August 23, the pulling effect of innovative drugs on its performance in the first half of the year became more and more obvious, with a total revenue of 3.
49 billion yuan, accounting for 22.
9% of the total revenue of 15.
19 billion yuan, an increase of 14.
2%
year-on-year.

The company also expects that the revenue of innovative drugs will account for 24% this year, and the revenue of innovative drugs is expected to exceed 10 billion yuan
by 2023.

As an innovative pharmaceutical company that successfully transformed into an innovation-driven performance growth, Hansen Pharmaceutical received revenue from innovative drugs of about RMB2.
321 billion in the first half of the year, an increase of about 84.
8% year-on-year, accounting for about 52.
3% of the total revenue (4.
434 billion yuan), compared with 28.
5% in the same period last year, which also set a new high
.

The industry believes that with the normalization of collection and the promotion of medical insurance control fees, the pharmaceutical industry has accelerated its transformation towards innovation, but due to the increase in the number of entrants in some popular tracks, homogenization competition is fierce, and the industry is also facing a reshuffle
.

The above-mentioned pharmaceutical companies have laid out innovative transformations in advance, so that the innovative drugs that have entered the harvest period have brought growth momentum
to the company.

Behind the strong innovation of a pharmaceutical company, it is inseparable from the huge investment in
research and development of the company.

In the case of China Biopharmaceutical, which is optimistic about the revenue of innovative drugs in the whole year, the company's R&D investment in the first half of the year reached 2.
19 billion yuan, an increase of 16.
5% year-on-year, accounting for 14.
4%, a record high; Hansen Pharmaceutical's R&D investment in the first half of the year also continued to grow, with a cumulative investment of about 739 million yuan, accounting for about 16.
7% of revenue; Simcere Pharmaceutical invested 652 million yuan in R&D expenses in the first half of the year, accounting for 24.
1%
of revenue.

According to industry statistics, more than 70% of the innovative pharmaceutical companies that have been disclosed in the report have achieved R&D investment growth, of which, among the innovative pharmaceutical companies with an investment of more than 1 billion yuan, in addition to China Biopharmaceuticals, there are also 6 pharmaceutical companies
such as BeiGene, Hengrui, Junshi Biological, CSPC, and Huang Pharmaceutical.

BeiGene's R&D expenditure in the first half of the year exceeded 5 billion yuan, reaching 5.
016 billion yuan, an increase of 20.
82%
compared with the same period last year.

The company's large R & D investment is mainly used for pre-bed research, clinical trials, cooperative research and development of product pipelines
.

It is through continuous investment in research and development that the innovative achievements of pharmaceutical companies have gradually achieved multi-point flowering
.

According to the report, at present, Simcere Pharmaceutical has nearly 60 innovative drug research and development pipelines, including 8 phase III clinical trials, 5 phase II clinical trials, and 6 phase I clinical trials; Hansen Pharmaceutical currently has more than 25 innovative drug projects at different stages of clinical trials, and more than 40 clinical trials are being carried out, and 7 new products have been approved for the market in the first half of the year, including Inelizumab Injection (trade name: Xinyue), an innovative drug
approved for the treatment of adult patients with AQP4 antibody-positive NMOSD.

From the perspective of the entire innovative drug environment, although since the release of the new policy on CDE anti-tumor drug research and development in November 2021, the investment intensity of the entire market has gradually calmed down, and the valuation has declined
.

However, many innovative drug companies still have confidence in the development of the innovative drug business, such as Simcere Pharmaceutical said at the performance conference that the company will continue to invest in the research and development of the innovative drug business, increase the density of talents, and activate the entire organization
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.